Status:
WITHDRAWN
Retroviral Insertion Site Methodology Study
Lead Sponsor:
Fondazione Telethon
Conditions:
Immune System Diseases
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
Adenosine deaminase (ADA) is an enzyme involved in the development and functioning of the immune system. Deficiency of ADA results in severe combined immunodeficiency (SCID), a fatal inherited immune ...
Eligibility Criteria
Inclusion
- Male or female, pediatric or adult, subjects with ADA-SCID, who have been previously treated with Strimvelis.
- Capable of giving signed informed consent or signed informed consent provided by the subject's parent or legal guardian.
Exclusion
- Presence of concomitant condition(s) that in the Investigator's opinion makes participation in the study unsuitable or may prevent compliance with the protocol requirements.
- Unlikely to comply with the requirements of the protocol (i.e. attendance for blood sampling on an approximately annual basis).
- Transportation of viable samples to the European Union (EU) central laboratory from the subject's home country is not possible.
Key Trial Info
Start Date :
June 25 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 9 2020
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03311074
Start Date
June 25 2020
End Date
July 9 2020
Last Update
January 29 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.